These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 31075399)
1. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation. Zhang M; Wang B; Urabe G; Huang Y; Plutzky J; Kent KC; Guo LW Cell Signal; 2019 Sep; 61():20-29. PubMed ID: 31075399 [TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT. Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650 [TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702 [TBL] [Abstract][Full Text] [Related]
5. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. Vollmuth F; Blankenfeldt W; Geyer M J Biol Chem; 2009 Dec; 284(52):36547-36556. PubMed ID: 19828451 [TBL] [Abstract][Full Text] [Related]
6. miRNA-200c-3p promotes endothelial to mesenchymal transition and neointimal hyperplasia in artery bypass grafts. Chen D; Zhang C; Chen J; Yang M; Afzal TA; An W; Maguire EM; He S; Luo J; Wang X; Zhao Y; Wu Q; Xiao Q J Pathol; 2021 Feb; 253(2):209-224. PubMed ID: 33125708 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations. Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780 [TBL] [Abstract][Full Text] [Related]
8. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation. Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677 [TBL] [Abstract][Full Text] [Related]
9. Discovery of Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999 [TBL] [Abstract][Full Text] [Related]
10. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators. Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908 [TBL] [Abstract][Full Text] [Related]
11. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails. Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820 [TBL] [Abstract][Full Text] [Related]
12. FAM222A, Part of the BET-Regulated Basal Endothelial Transcriptome, Is a Novel Determinant of Endothelial Biology and Angiogenesis-Brief Report. Tzani A; Haemmig S; Cheng HS; Pérez-Cremades D; Heuschkel MA; Jamaiyar A; Singh SA; Aikawa M; Yu PB; Wang T; Sun Y; Feinberg MW; Plutzky J Arterioscler Thromb Vasc Biol; 2024 Jan; 44(1):143-155. PubMed ID: 37942611 [TBL] [Abstract][Full Text] [Related]
13. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4. Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047 [TBL] [Abstract][Full Text] [Related]
14. Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility. Wernersson S; Bobby R; Flavell L; Milbradt AG; Holdgate GA; Embrey KJ; Akke M Biochemistry; 2022 Nov; 61(21):2303-2318. PubMed ID: 36215732 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4. Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120 [TBL] [Abstract][Full Text] [Related]
16. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy. Yang GJ; Wang W; Lei PM; Leung CH; Ma DL Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796 [TBL] [Abstract][Full Text] [Related]
17. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893 [TBL] [Abstract][Full Text] [Related]
18. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations. Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214 [TBL] [Abstract][Full Text] [Related]